Nucleus RadioPharma

Nucleus RadioPharma is a contract development and manufacturing organization (CDMO) dedicated to the development and manufacturing of targeted radiotherapies. Founded in 2022 by Eclipse Ventures and Mayo Clinic, the company aims to address the challenges faced in the production and supply chain of radiopharmaceuticals. These specialized drugs offer a highly targeted approach to various cancer types and stages, with the potential to treat many cancers.

Nucleus RadioPharma's core mission is to ensure cancer patients can access potentially lifesaving radiopharmaceuticals by developing technologies to modernize the clinical development, manufacturing, and supply chain processes. The company's innovative approach involves establishing multiple large regional manufacturing facilities across the US. The first facility, spanning 12,000 square feet, is located near the Mayo Clinic in Rochester, Minnesota, and is expected to be operational by mid-2024.

To enhance its manufacturing capabilities, Nucleus RadioPharma has secured a USD 56 million Series A funding round led by Eclipse and GE healthcare, with participation from other investors such as Mayo Clinic and Fox Chase Cancer Center. This funding will enable the establishment of additional manufacturing sites and the development of novel technologies for the production, distribution, and delivery of radiopharmaceuticals.

Nucleus RadioPharma's technology platforms are designed to advance new therapies through clinical trials to commercialization. The company provides a range of services, including formulation development, analytical method development, regulatory documentation, and drug product manufacturing. Its flexible approach allows for multiple onboarding points to accommodate innovators at various stages of their product lifecycle.

In November 2023, Nucleus RadioPharma partnered with SHINE Technologies, the largest producer of lutetium-177 in North America, to secure a long-term supply of this vital component for targeted radiopharmaceutical treatments. This agreement ensures a reliable and consistent supply of lutetium-177, a crucial element in cutting-edge medical treatments for neuroendocrine tumors and prostate cancer.